

Yusuf Yazici

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6035052/publications.pdf>

Version: 2024-02-01

65
papers

1,292
citations

567281

15
h-index

361022

35
g-index

66
all docs

66
docs citations

66
times ranked

1686
citing authors

#	ARTICLE	IF	CITATIONS
1	Behçet syndrome: a contemporary view. <i>Nature Reviews Rheumatology</i> , 2018, 14, 107-119.	8.0	281
2	Apremilast for Behçet's Syndrome – A Phase 2, Placebo-Controlled Study. <i>New England Journal of Medicine</i> , 2015, 372, 1510-1518.	27.0	204
3	Trial of Apremilast for Oral Ulcers in Behçet's Syndrome. <i>New England Journal of Medicine</i> , 2019, 381, 1918-1928.	27.0	125
4	Behçet's Syndrome. <i>Current Rheumatology Reports</i> , 2010, 12, 429-435.	4.7	115
5	Behçet syndrome. <i>Nature Reviews Disease Primers</i> , 2021, 7, 67.	30.5	75
6	Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy. <i>Bulletin of the NYU Hospital for Joint Diseases</i> , 2008, 66, 77-85.	0.7	67
7	Ocular Involvement of Behçet's Syndrome: a Comprehensive Review. <i>Clinical Reviews in Allergy and Immunology</i> , 2015, 49, 298-306.	6.5	53
8	Criteria for Behçet's disease with reflections on all disease criteria. <i>Journal of Autoimmunity</i> , 2014, 48-49, 104-107.	6.5	50
9	Treatment of rheumatoid arthritis: we are getting there. <i>Lancet, The</i> , 2009, 374, 178-180.	13.7	34
10	Limitations of clinical trials in chronic diseases: is the efficacy of methotrexate (MTX) underestimated in polyarticular psoriatic arthritis on the basis of limitations of clinical trials more than on limitations of MTX, as was seen in rheumatoid arthritis?. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S82-93.	0.8	23
11	Core Set of Domains for Outcome Measures in Behçet's Syndrome. <i>Arthritis Care and Research</i> , 2022, 74, 691-699.	3.4	21
12	Biomarkers in vasculitis. <i>Current Opinion in Rheumatology</i> , 2018, 30, 30-35.	4.3	19
13	MDHAQ/RAPID3 scores in patients with osteoarthritis are similar to or higher than in patients with rheumatoid arthritis: a cross-sectional study from current routine rheumatology care at four sites. <i>RMD Open</i> , 2017, 3, e000391.	3.8	18
14	Some concerns about adverse event reporting in randomized clinical trials. <i>Bulletin of the NYU Hospital for Joint Diseases</i> , 2008, 66, 143-5.	0.7	16
15	Promising new treatments for rheumatoid arthritis - the kinase inhibitors. <i>Bulletin of the NYU Hospital for Joint Diseases</i> , 2011, 69, 233-7.	0.7	16
16	Treat-to-target: measures. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, S7-9.	0.8	15
17	Differences in clinical manifestations, treatment, and concordance rates with two major sets of criteria for Behçet's syndrome for patients in the US and Japan: data from a large, three-center cohort study. <i>Modern Rheumatology</i> , 2013, 23, 547-553.	1.8	14
18	A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post-hoc results from the certolizumab pegol phase 4 PREDICT trial. <i>Arthritis Research and Therapy</i> , 2017, 19, 215.	3.5	14

#	ARTICLE	IF	CITATIONS
19	Apremilast for oral ulcers associated with active Behçet's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 80-87.	0.8	13
20	Disease activity measures at baseline predict structural damage progression: data from the randomized, controlled AMPLE and AVERT trials. <i>Rheumatology</i> , 2020, 59, 2090-2098.	1.9	10
21	Management of Behçet syndrome. <i>Current Opinion in Rheumatology</i> , 2020, 32, 35-40.	4.3	10
22	Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison. <i>European Journal of Rheumatology</i> , 2018, 5, 216-223.	0.6	8
23	Diagnosis and/or classification of vasculitis. <i>Current Opinion in Rheumatology</i> , 2016, 28, 3-7.	4.3	7
24	MBDA: what is it good for?. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, e72-e72.	0.9	6
25	Vasculitis 2018: the bench and the bedside. <i>Current Opinion in Rheumatology</i> , 2018, 30, 1-3.	4.3	6
26	Editorial: A review of vasculitis 2019: an introduction. <i>Current Opinion in Rheumatology</i> , 2019, 31, 1-2.	4.3	6
27	The spectrum of early rheumatoid arthritis practice across the globe: results from a multinational cross sectional survey. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 477-483.	0.8	5
28	Osteoarthritis is as severe as rheumatoid arthritis: evidence over 40 years according to the same measure in each disease. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 120, 7-17.	0.8	5
29	There was less self-critique among basic than in clinical science articles in three rheumatology journals. <i>Journal of Clinical Epidemiology</i> , 2014, 67, 654-657.	5.0	4
30	Recommendations in the American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis Related to the Use of Biologic Agents in Patients With a History of Cancer Need Reconsideration: Comment on the Article by Singh et al. <i>Arthritis and Rheumatology</i> , 2016, 68, 1315-1316.	5.6	4
31	Vasculitis update, 2007. <i>Bulletin of the NYU Hospital for Joint Diseases</i> , 2007, 65, 212-4.	0.7	4
32	Informed consent: time for more transparency. <i>Arthritis Research and Therapy</i> , 2010, 12, 121.	3.5	3
33	Wnt Signaling in Osteoarthritis: a 2017 Update. <i>Current Treatment Options in Rheumatology</i> , 2017, 3, 101-111.	1.4	3
34	Comment on: "It can't be zero!" Difficulties in completing patient global assessment in rheumatoid arthritis: a mixed methods study. <i>Rheumatology</i> , 2021, 60, e28-e29.	1.9	3
35	Rheumatoid arthritis treatment and monitoring of outcomes—where are we [corrected] in 2007?. <i>Bulletin of the NYU Hospital for Joint Diseases</i> , 2007, 65, 300-5.	0.7	3
36	Systemic vasculitis treatment and monitoring update, 2008. <i>Bulletin of the NYU Hospital for Joint Diseases</i> , 2008, 66, 228-30.	0.7	3

#	ARTICLE	IF	CITATIONS
37	Safety reporting in randomized clinical trials - a need for improvement. Bulletin of the NYU Hospital for Joint Diseases, 2009, 67, 209-10.	0.7	3
38	Pulmonary artery aneurysms in Behçet's syndrome: a review of the literature with emphasis on geographical differences. Clinical and Experimental Rheumatology, 2015, 33, S54-9.	0.8	3
39	Initial visit symptoms in probable Behçet's syndrome is predictive of ISG criteria fulfillment in Behçet's syndrome: data from New York and Amsterdam cohorts. Clinical and Experimental Rheumatology, 2021, 39, 43-46.	0.8	3
40	Impact of apremilast on quality of life in Behçet's syndrome: analysis of the phase 3 RELIEF study. RMD Open, 2022, 8, e002235.	3.8	3
41	Treatment options for rheumatoid arthritis beyond TNF- α inhibitors. Expert Review of Clinical Pharmacology, 2010, 3, 663-666.	3.1	2
42	Recommendations in the American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis Related to the Use of Biologic Agents in Patients With a History of Cancer Need Reconsideration: Comment on the Article by Singh et al. Arthritis Care and Research, 2016, 68, 724-724.	3.4	2
43	Apremilast for the treatment of Behçet's syndrome. Expert Opinion on Orphan Drugs, 2017, 5, 677-681.	0.8	2
44	THU0303...THE OMERACT CORE DOMAIN SET FOR CLINICAL TRIALS IN BEHÇET'S SYNDROME. , 2019, , .		2
45	Monitoring response to treatment in rheumatoid arthritis--which tool is best suited for routine "real world" care?. Bulletin of the NYU Hospital for Joint Diseases, 2007, 65 Suppl 1, S25-8.	0.7	2
46	Comparative effectiveness of secukinumab and golimumab in ankylosing spondylitis assessed by matching-adjusted indirect comparison using pivotal phase III clinical trial data. Rheumatology, 2018, 57, .	1.9	1
47	Assessing the possible association of anti-TNF use with new malignancies: A neglected methodological consideration. Pharmacoepidemiology and Drug Safety, 2018, 27, 894-901.	1.9	1
48	Editorial: Introduction, vasculitis 2020. Current Opinion in Rheumatology, 2020, 32, 1-2.	4.3	1
49	Monitoring outcomes of arthritis and longitudinal data collection using patient questionnaires in routine care. Bulletin of the NYU Hospital for Joint Diseases, 2006, 64, 40-4.	0.7	1
50	Informed consent--practical considerations. Bulletin of the NYU Hospital for Joint Diseases, 2010, 68, 127-9.	0.7	1
51	Kinase inhibitors for the treatment of rheumatoid arthritis. Bulletin of the NYU Hospital for Joint Diseases, 2012, 70, 204-7.	0.7	1
52	Letter from the Editor. Biologics in Therapy, 2011, 1, 2.	1.8	0
53	Severe adverse reactions are rare with infusions of infliximab in a community setting. Evidence-based Nursing, 2011, 13, 107-108.	0.2	0
54	Is there a direct relationship between serum level of methotrexate and clinical efficacy and tolerability?. Annals of the Rheumatic Diseases, 2014, 73, e54-e54.	0.9	0

#	ARTICLE	IF	CITATIONS
55	AB0737â€¦..ACHIEVEMENT OF RAPID3 NEAR REMISSION OR LOW SEVERITY IS ASSOCIATED WITH RESIDUAL LEVELS OF ARTICULAR AND EXTRA-ARTICULAR MANIFESTATIONS OF ACTIVE PSORIATIC ARTHRITIS IN SUBJECTS TREATED WITH APREMILAST. , 2019, , .		0
56	Functional Status Measures and Indices in Rheumatoid Arthritis: Comment on the Articles by Barber et al and England et al. Arthritis Care and Research, 2020, 72, 1185-1186.	3.4	0
57	Correspondence on â€˜classification criteria: time for a rethink â€™by D Porter<i>et alâ€™™</i>. Annals of the Rheumatic Diseases, 2023, 82, e176-e176.	0.9	0
58	The relationship between body composition, disease activity, and functional status in adults with rheumatoid arthritis (1031.15). FASEB Journal, 2014, 28, 1031.15.	0.5	0
59	Editorial: Introduction, Vasculitis 2021. Current Opinion in Rheumatology, 2022, 34, 1-3.	4.3	0
60	Databases in routine care: possible and necessary. Bulletin of the NYU Hospital for Joint Diseases, 2007, 65, 127-31.	0.7	0
61	Corticosteroids as disease modifying drugs in rheumatoid arthritis treatment. Bulletin of the NYU Hospital for Joint Diseases, 2012, 70 Suppl 1, 11-3.	0.7	0
62	Effect size, the misnomer. Clinical and Experimental Rheumatology, 2021, , .	0.8	0
63	Initial visit symptoms in probable BehçŞet's syndrome is predictive of ISC criteria fulfillment in BehçŞet's syndrome: data from New York and Amsterdam cohorts. Clinical and Experimental Rheumatology, 2021, 39 Suppl 132, 43-46.	0.8	0
64	Apremilast for oral ulcers associated with active BehçŞet's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial. Clinical and Experimental Rheumatology, 2021, 39 Suppl 132, 80-87.	0.8	0
65	Effect size, the misnomer. Clinical and Experimental Rheumatology, 0, , .	0.8	0